我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

附子理中汤治疗溃疡性结肠炎效果的Meta分析*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2018年05期
页码:
27-31
栏目:
临床研究
出版日期:
2019-06-24

文章信息/Info

Title:
Meta-analysis of Efficacy of Fuzi Lizhong Decoction in Treatment of Ulcerative Colitis
文章编号:
1000-2723(2018)05-0027-0
作者:
刘佳丽1杨 坤1徐爱玲1刘一东1谷雪松1孙平良2△
(1. 广西中医药大学,广西 南宁 530001;2. 广西中医药大学第一附属医院,广西 南宁 530023)
Author(s):
LIU Jiali1 YANG Kun1 XU Ailing1 LIU Yidong1 GU Xuesong1 SUN Pingliang2
(1. Postgraduate College of Guangxi Chinese Medicine University, Nanning 530001, China; 2. The First Affiliated Hospital of Guangxi Chinese Medicine University, Department of Anorectal Surgery, Nanning 530023, China)
关键词:
附子理中汤 溃疡性结肠炎 Meta分析
Keywords:
Fuzi Lizhong ulcertive colitis meta-analysis
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2018.05.006
文献标识码:
A
摘要:
目的 系统评价附子理中汤加减治疗溃疡性结肠炎(UC)的有效性与安全性。方法 计算机检索PubMed,The Cochrane Library,Embase,Web of Knowledge,Allied and Complementary Madicine,OpenGrey,CBM,Wanfang Data,VIP和CNKI数据库,查找附子理中汤加减为干预措施治疗UC的随机对照试验,检索时限均从建库至2018年05月15日。收集纳入研究的总有效率、腹泻、脓血便的症状改善、结肠内镜积分和不良反应,进行Meta分析。结果 共纳入8个研究,共计730例患者。Meta分析示,对比单用西药,附子理中汤加减联用西药和单用附子理中汤加减疗效的合并RR值分别为1.20[95% CI(1.08,1.32)],1.22[95% CI(1.12,1.33)],存在统计学意义(P<0.05),且单用附子理中汤加减能降低不良反应发生率。敏感性分析和漏斗图分析显示纳入的文献同质性较强,不存在发表偏倚。结论 对比单用西药,单用附子理中汤加减与附子理中汤加减联合西药治疗溃疡性结肠炎有更好的临床疗效。单用附子理中汤加减治疗溃疡性结肠炎疗效在总有效率与降低不良反应方面优于西药治疗,但由于纳入文献数目较少,纳入文献的质量不高,需要高质量的大样本双盲随机对照试验的支持。
Abstract:
Objective To discuss the effectiveness and safety of Fuzi Lizhong decoction in the treatment of ulcerative colitis. Methods Databases such as PubMed, The Cochrane Library, Embase, Web of Knowledge, Allied and Complementary Madicine, OpenGrey, CBM, Wanfang Data, VIP and CNKI were searched for the randomized controlled trials(RCT)about Fuzi Lizhong decoction combined with western medicines and western medicine in treating ulcerative colitis from database creation to May 15th, 2018. Their qualities were assessed by the Cochrane scale. The therapies, sample size, clinical efficacy, endoscopic improvement and adverse events of the included literatures were collected. A Meta-analysis was made on the efficacy and adverse events. Results A total of 8 studies involving 730 patients were included. The results of Meta-analysis showed that, compared with western medicines, Fuzi Lizhong decoction and Fuzi Lizhong decoction combined with western medicines the combined RR of the effective rate of 1.20[95% CI(1.08, 1.32)], 1.22[95% CI(1.12, 1.33)], with statistical significance(P<0.05), and significantly reduce the incidence of adverse reactions. The sensitivity analysis and funnel plot analysis showed a higher homogeneity in the literatures and no evidence of publication bias. Conclusion Compared with western medicines, Fuzi Lizhong decoction and Fuzi Lizhong decoction combined with western medicines is batter than western medicines in terms of curative rate and adverse reactions. But it still needs more large-sample-size double-blind RCTs shall be included to support this conclusion.

参考文献/References

[1]葛均波,徐永健. 内科学[M]. 北京:人民卫生出版社,2013:385-390.
[2] ISKANDAR H N,DHERE T,FARRAYE F A. Ulcerative Colitis:Update on Medical Management[J]. Curr Gastroenterol Rep,2015,17(11):44.
[3] DIGNASS A,LINDSAY J O,STURM A,et al. Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 1: definiciones y diagnóstico(versiónespa?觡ola)[J]. Rev De Gastroenterol Méx,2014,79(4):263-289.
[4] 欧阳钦,潘国宗,温忠慧,等. 对炎症性肠病诊断治疗规范的建议[J]. 中华消化杂志,2001,40(2):138-141.
[5] 中华人民共和国卫生部. 中药新药临床研究指导原则(第3辑)[S]. 1997:61.
[6] 李慧儒. 附子理中芍桂汤加减治疗慢性溃疡性结肠炎98例[J]. 现代中医药,2007,27(2):24-25.
[7] 伍艳靖,李尔勤. 中西医结合治疗溃疡性结肠炎的临床观察与护理[J]. 全科护理,2011,9(15):1353-1354.
[8] 余沅林. 附子理中汤加味联合柳氮磺胺吡啶治疗溃疡性结肠炎的效果观察[J]. 当代医学,2016,22(35):192-193.
[9] 余海平,张建兴,李春耕. 附子理中汤加味治疗慢性溃疡性结肠炎的临床评价[J]. 中国药业,2017,26(13):67-69.
[10] 刘彩莉,李卫河. 附子理中痛泻白头翁合方治疗溃疡性结肠炎[J]. 新乡医学院学报,1997,14(1):72-74.
[11] 胡利群,张莲香,张连凤. 附子理中丸联合五维他口服溶液治疗慢性溃疡性结肠炎的疗效观察与分析[J]. 中国医学创新,2012,9(3):123-124.
[12] 肖福香,万莉华,陈舞燕. 加味附子理中汤应用于脾肾阳虚型溃疡性结肠炎治疗的有效性分析[J]. 数理医药学杂志,2016,29(6):874-875.
[13] 陈军,鲁磊,刘志国. 加味附子理中汤治疗脾肾阳虚型溃疡性结肠炎疗效观察[J]. 中国中西医结合消化杂志,2014,22(10):624-625.
[14] 石磊,施丽婕. 溃疡性结肠炎中西医发病机制研究[J]. 长春中医药大学学报,2014,30(6):1173-1176.
[15] 王燕,段永强,朱向东,等. 基于“脾肾相关”探讨中医干预溃疡性结肠炎疗效机制[J]. 中国中医药信息杂志,20l5,22(2):99-101.
[16] 申旭龙,唐学贵,任敏,等. 溃疡性结肠炎指南共识中的整体观念[J]. 中国肛肠病杂志,2015,35(8):55-57.
[17] 陈四辈,盛长健,邹晓华. 加味溃愈汤联合柳氮磺胺吡啶治疗溃疡性结肠炎临床观察[J]. 中医药临床杂志,2011,23(3):239-241.
[18] 秦成男,韩国庆. 溃疡性并合肠失氨基水杨酸类药物和皮质类固醇药物治疗[J]. 世界华人消化杂志,2012,8(3):338-339.
[19] 席作武,刘文清,王凯. 惠迪口服液联合加味附子理中汤保留灌肠治疗脾肾阳虚型溃疡性结肠炎临床研究[J]. 中医学报,2011,26(9):1114-1116.
[20] 姬培震,张怡,李雪萍,等. 附子理中汤灌肠对脾肾阳虚型溃疡性结肠炎大鼠NF-κB,TNF-α,IL-1β表达的影响[J]. 中国实验方剂学杂志,2015,21(14):124-128.
[21] 朱丹. 附子理中汤灌肠对溃疡性结肠炎脾肾阳虚型大鼠血清TNF-α,IL-1β,IL-6水平的影响[D]. 成都:成都中医药大学,2015.

备注/Memo

备注/Memo:
收稿日期: 2018 - 10- 13
* 基金项目: 国家自然科学基金项目(81660795);广西自然科学基金项目(2017gXNSFAA198303)
第一作者简介: 刘佳丽(1993-),女,在读硕士研究生,研究方向:肛肠疾病诊治。
△通信作者: 孙平良,E-mail:sunpl2000@163.com
更新日期/Last Update: 2019-06-25